![](/aaproduct/mf/image/left_menu_main.GIF) |
|
|
![](/aaproduct/mf/image/left_menu_group_1.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_all.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_1.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_2.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_3.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_4.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_5.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_8.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_6.GIF) |
|
![](/aaproduct/mf/image/left_menu_product_9.gif) |
|
|
![](/aaproduct/mf/image/left_menu_group_3.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_1.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_2.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_3.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_4.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_5.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_6.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_7.GIF) |
|
![](/aaproduct/mf/image/left_menu_application_8.GIF) |
|
|
![](/aaproduct/mf/image/left_menu_group_2.GIF) |
|
![](/aaproduct/mf/image/left_menu_feature_1.GIF) |
|
![](/aaproduct/mf/image/left_menu_feature_2.GIF) |
|
![](/aaproduct/mf/image/left_menu_feature_3.GIF) |
|
![](/aaproduct/mf/image/left_menu_feature_8.GIF) |
|
![](/aaproduct/mf/image/left_menu_feature_9.GIF) |
|
|
![](/aaproduct/mf/image/left_menu_catalog.gif) |
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
491     |
  Yesterday |
1204     |
  Since 2006 |
1,820,821     |
|
|
![](/aacommon/image/catalog_2024.gif) |
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
Microfluidics »ç´Â 2022³â ¹Ì±¹ º¸½ºÅæ¿¡¼ °³ÃÖµÈ RNA Therapeutics & Delivery U.S. Congress ¿¡ Âü°¡ÇÏ¿´½À´Ï´Ù.
À̹ø Congress ¿¡¼´Â ÃÖ½ÅÀÇ RNA formulation & clinical development, RNA Delivery Strategies µî¿¡ °üÇÑ
¸¹Àº ¹ßÇ¥°¡ ÀÖ¾ú½À´Ï´Ù.
Yang Su ¹Ú»ç (Ph.D., Microfluidics, Manager of New Technology and Applications) ´Â ÀÌ Congress ¿¡¼
´ÙÀ½°ú °°Àº ÁÖÁ¦·Î ¼¼¹Ì³ª ¹ßÇ¥¸¦ ÇÏ¿´½À´Ï´Ù.
Microfluidizer¢ç Technology:
A cGMP Technology That Can Help with Scale Up for Both Viral and Non-viral RNA Delivery Platforms
Dr. Yang Su ´Â viral and lipid-based nanoparticle non-viral vectors °¡ ¾î¶»°Ô È¿À²ÀûÀÎ RNA Delivery Platform À¸·Î °ËÁõµÇ°í ÀÖ´ÂÁö?
±×¸®°í Microfluidizer¢ç technology ´Â ¾î¶»°Ô ÀÌ delivery system µéÀÇ Á¦Á¶¿¡ È¿À²ÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ´ÂÁö¿¡ ´ëÇØ ¼³¸íÇÏ¿´½À´Ï´Ù.
Dr. Yang Su ÀÇ ¼¼¹Ì³ª ¹ßÇ¥ topic Àº ´ÙÀ½°ú °°½À´Ï´Ù.
![](/aasource_image/circle_gray_27.gif) |
Drug delivering nanoparticles and challenges during development and manufacturing. |
![](/aasource_image/circle_gray_27.gif) |
Overall benefits of Microfluidizer¢ç technology for addressing nanotechnology applications. |
![](/aasource_image/circle_gray_27.gif) |
Microfluidizer¢ç technology's role in achieving repeatable, scalable results - batch-to-batch and from lab to pilot to production volumes. |
|
|
|
|